NYSE: BHCBausch Health Companies Inc Stock
$7.94-0.29 (-3.52%)
Updated Jun 5, 2023
BHC Price
$7.94
Fair Value Price
N/A
Market Cap
$2.89B
52 Week Low
$4.00
52 Week High
$10.23
P/E
-8.1x
P/B
-3.61x
P/S
0.36x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.15B
Earnings
-$357.00M
Gross Margin
70.6%
Operating Margin
15.02%
Profit Margin
-4.4%
Debt to Equity
-31.63
Operating Cash Flow
-$511M
Beta
1.38
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BHC Overview
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BHC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BHC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BHC is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
BHC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more BHC due diligence checks available for Premium users.
Be the first to know about important BHC news, forecast changes, insider trades & much more!
BHC News
Valuation
BHC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.1x
Industry
14.98x
Market
53.21x
BHC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.61x
Industry
1.78x
BHC's financial health
Profit margin
Revenue
$1.9B
Net Income
-$201.0M
Profit Margin
-10.3%
BHC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BHC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$25.4B
Liabilities
$25.3B
Debt to equity
-31.63
BHC's short-term assets ($4.24B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BHC's long-term liabilities ($21.38B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BHC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BHC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$154.0M
Investing
-$78.0M
Financing
-$142.0M
BHC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BHC vs Pharmaceutical Stocks
Bausch Health Companies Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.